Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019;59(2):98-100.
doi: 10.3960/jslrt.19006.

Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma

Dai Maruyama  1 , Hirokazu Nagai  2 , Noriko Fukuhara  3 , Toshiyuki Kitano  4 , Takayuki Ishikawa  5 , Tomoaki Nishikawa  6
Affiliations
Clinical Trial

Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma

Dai Maruyama et al. J Clin Exp Hematop. 2019.
No abstract available

Keywords: Japanese patients; covalent BTK inhibitor; ibrutinib; mantle cell lymphoma; phase II clinical trial.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST: Dai Maruyama has received honoraria from Janssen, and has received research funding from Janssen. Hirokazu Nagai has received honoraria from Eisai, Chugai, Mundipharma, and Takeda, and has received research funding from AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Janssen, Gilead, Mundipharma, Ono, Otsuka, and Takeda. Noriko Fukuhara has received research funding from AbbVie, Bayer, Eisai, Gilead, Janssen, Ono, and Takeda. Toshiyuki Kitano and Takayuki Ishikawa have no conflicts of interest to declare. Tomoaki Nishikawa is an employee of Janssen.

Figures

Fig 1
Fig 1
(A) Investigator-assessed best response and (B) individual responses.* *Each bar represents 1 patient in the study. Right arrow cap indicates censored. Bars without an arrow indicate non-censored. Overall survival is represented by the total length of the bar. The section after the line has stopped indicates the length of time the patient was monitored. Progression-free survival is represented by the length of the bar from the left to the circle, or the full length of the bar if there is no circle denoting progressive disease. Duration of response is represented by the length of the line from the triangle to the circle, or the full length of the line if no circle. CI, confidence interval; CR, complete response; ORR, overall response rate; PR, partial response; SD, stable disease.
See this image and copyright information in PMC

References

    1. Maruyama D, Nagai H, Fukuhara N, et al. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. Cancer Sci. 2016; 107: 1785-1790. 10.1111/cas.13076 - DOI - PMC - PubMed

MeSH terms